TY - JOUR
T1 - Rygnings og rygestopmidlers interaktion med lægemidler
AU - Madsen, Helle Karkov Lindberg
AU - Gulløv, Mette
AU - Farver-Vestergaard, Ingeborg
AU - Hjorth, Peter
AU - Nielsen, Lars Peter
AU - Ottesen, Anders Løkke
AU - Haastrup, Maija Bruun
PY - 2023/3/20
Y1 - 2023/3/20
N2 - Tobacco smoke can cause drug interactions by induction of CYP1A2, which metabolizes drugs like clozapine, olanzapine and theophylline. This means that smokers need higher doses to achieve the same plasma concentrations as non-smokers. Furthermore, smoking cessation can cause an increase in plasma concentrations of drugs metabolised by CYP1A2, which in turn may lead to adverse effects. Of the drugs used for smoking cessation only bupropione has clinically relevant interactions. All of these situations may be handled by dose adjustment.
AB - Tobacco smoke can cause drug interactions by induction of CYP1A2, which metabolizes drugs like clozapine, olanzapine and theophylline. This means that smokers need higher doses to achieve the same plasma concentrations as non-smokers. Furthermore, smoking cessation can cause an increase in plasma concentrations of drugs metabolised by CYP1A2, which in turn may lead to adverse effects. Of the drugs used for smoking cessation only bupropione has clinically relevant interactions. All of these situations may be handled by dose adjustment.
KW - Clozapine/adverse effects
KW - Cytochrome P-450 CYP1A2/metabolism
KW - Drug Interactions
KW - Humans
KW - Olanzapine
KW - Smoking Cessation
M3 - Tidsskriftartikel
C2 - 36065858
AN - SCOPUS:85137189507
VL - 185
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 6
M1 - V02220117
ER -